DK1635799T3 - Farmaceutiske formuleringer af amyloidinhiberende forbindelser - Google Patents
Farmaceutiske formuleringer af amyloidinhiberende forbindelserInfo
- Publication number
- DK1635799T3 DK1635799T3 DK04744039T DK04744039T DK1635799T3 DK 1635799 T3 DK1635799 T3 DK 1635799T3 DK 04744039 T DK04744039 T DK 04744039T DK 04744039 T DK04744039 T DK 04744039T DK 1635799 T3 DK1635799 T3 DK 1635799T3
- Authority
- DK
- Denmark
- Prior art keywords
- amyloid
- pharmaceutical formulations
- inhibiting compounds
- methods
- therapeutic formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US48098403P | 2003-06-23 | 2003-06-23 | |
| US51211603P | 2003-10-17 | 2003-10-17 | |
| US10/871,549 US20050142191A1 (en) | 2003-06-23 | 2004-06-18 | Pharmaceutical formulations of amyloid inhibiting compounds |
| PCT/IB2004/002381 WO2004112762A2 (en) | 2003-06-23 | 2004-06-21 | Pharmaceutical formulations of amyloid inhibiting compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1635799T3 true DK1635799T3 (da) | 2009-11-23 |
Family
ID=33545348
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK04744039T DK1635799T3 (da) | 2003-06-23 | 2004-06-21 | Farmaceutiske formuleringer af amyloidinhiberende forbindelser |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US20050142191A1 (da) |
| EP (2) | EP1635799B1 (da) |
| JP (1) | JP4903561B2 (da) |
| CN (1) | CN103550196A (da) |
| AT (1) | ATE438391T1 (da) |
| AU (2) | AU2004248995B2 (da) |
| BR (1) | BRPI0411808A (da) |
| CA (1) | CA2529268C (da) |
| DE (1) | DE602004022408D1 (da) |
| DK (1) | DK1635799T3 (da) |
| ES (1) | ES2328818T3 (da) |
| IL (1) | IL172193A0 (da) |
| MX (1) | MXPA05013974A (da) |
| NZ (1) | NZ544685A (da) |
| PL (1) | PL1635799T3 (da) |
| PT (1) | PT1635799E (da) |
| SI (1) | SI1635799T1 (da) |
| WO (1) | WO2004112762A2 (da) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1276483B1 (en) * | 1999-04-28 | 2009-09-02 | BELLUS Health (International) Limited | Compositions and methods for treating amyloidosis using sulphonate derivatives |
| AU5994900A (en) * | 1999-07-09 | 2001-01-30 | Isis Innovation Limited | Compounds for inhibiting diseases and preparing cells for transplantation |
| EP1585520A1 (en) * | 2002-12-24 | 2005-10-19 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US20050142191A1 (en) | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| US20070010573A1 (en) * | 2003-06-23 | 2007-01-11 | Xianqi Kong | Methods and compositions for treating amyloid-related diseases |
| US7244764B2 (en) * | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| AU2005326962A1 (en) | 2004-12-22 | 2006-08-17 | Bellus Health (International) Limited | Methods and compositions for treating amyloid-related diseases |
| EP1890685A2 (en) * | 2005-04-12 | 2008-02-27 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| TW200716088A (en) * | 2005-04-15 | 2007-05-01 | Neurochem Int Ltd | Formulations and methods for treating amyloidosis |
| WO2007023389A2 (en) * | 2005-07-21 | 2007-03-01 | Neurochem (International) Limited | Polymorphic forms of 3-amino-1-propanesulfonic acid |
| SI2089417T1 (sl) | 2006-10-12 | 2015-04-30 | Bhi Limited Partnership | Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline |
| CA2673022A1 (en) * | 2006-12-22 | 2008-07-03 | Bellus Health (International) Limited | Methods, compounds, and compositions for treating metabolic disorders and diabetes |
| CA2727019A1 (en) * | 2008-06-10 | 2009-12-17 | Teva Pharmaceutical Industries Ltd. | Rasagiline soft gelatin capsules |
| JP2012505162A (ja) * | 2008-10-09 | 2012-03-01 | ワラタ ファーマシューティカルズ， インコーポレイテッド | 黄斑変性症関連障害を処置するためのｓｃｙｌｌｏ−イノシトールの使用 |
| US9735792B2 (en) | 2013-01-08 | 2017-08-15 | Rambus Inc. | Integrated circuit comprising circuitry to determine settings for an injection-locked oscillator |
| EP3119911B1 (en) | 2014-03-21 | 2023-08-09 | Alzheon, Inc. | Compounds for use in treating alzheimer's disease in apoe4+/+ patients |
| EP3347002B1 (en) | 2015-09-10 | 2023-06-07 | Alzheon, Inc. | Treatment of alzheimer's disease in a particular patient population |
| CN114805211A (zh) | 2017-03-21 | 2022-07-29 | 润佳（苏州）医药科技有限公司 | 同位素富集3-氨基-1-丙磺酸衍生物、药物组合物及其用途 |
| WO2023212289A1 (en) | 2022-04-28 | 2023-11-02 | Alzheon, Inc. | Tramiprosate for treating apoe4-related diseases |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3658966A (en) * | 1969-09-15 | 1972-04-25 | Kowa Co | Methods of treating hypertension |
| US3920833A (en) * | 1974-08-08 | 1975-11-18 | Stanley Drug Products Inc | Antifibrinolytic agents |
| US4255448A (en) * | 1979-09-10 | 1981-03-10 | Wisconsin Alumni Research Foundation | Method for reducing epileptiform activity |
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| EP0119274B1 (en) | 1982-09-08 | 1986-11-26 | MITSUI TOATSU CHEMICALS, Inc. | Process for producing aminoalkylsulfonic acids |
| US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
| MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| JP2642198B2 (ja) * | 1989-08-24 | 1997-08-20 | 元庸 村上 | 胃粘膜障害治療剤 |
| US5164295A (en) | 1991-03-06 | 1992-11-17 | The Upjohn Company | Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds |
| GB9117716D0 (en) | 1991-08-16 | 1991-10-02 | Lynxvale Ltd | Gaba derivatives and their therapeutic application |
| EP0600973A1 (en) | 1991-08-27 | 1994-06-15 | The Upjohn Company | A method for treatment of metabolic disorders and metabolism |
| US5643562A (en) | 1993-03-29 | 1997-07-01 | Queen's University Of Kingston | Method for treating amyloidosis |
| US5840294A (en) | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| US5972328A (en) * | 1993-03-29 | 1999-10-26 | Queen's University At Kingston | Method for treating amyloidosis |
| DK1060750T3 (da) * | 1993-03-29 | 2006-01-09 | Univ Kingston | Propan-1,3-disulfonsyre og dens farmaceutisk acceptable salte til behandling af amyloidose |
| JPH07223970A (ja) * | 1994-02-10 | 1995-08-22 | Tanabe Seiyaku Co Ltd | 消化管内適所放出製剤 |
| DE69528583T2 (de) * | 1994-04-22 | 2003-07-10 | Yamanouchi Pharma Co Ltd | Kolon-spezifisches arzneistofffreisetzungssystem |
| US5683718A (en) * | 1995-04-04 | 1997-11-04 | Time-Cap Labs, Inc. | Enteric coated tablet with raised identification character and method of manufacture |
| CA2229427A1 (en) * | 1995-09-12 | 1997-03-20 | The General Hospital Corporation | Method for early detection of ovarian cancer |
| AU703540B2 (en) | 1996-03-26 | 1999-03-25 | Meddiss, Incorporated | Methods for inducing analgesia or anesthesia and treating or preventing ischemic injury of tissues in general |
| GB9619074D0 (en) * | 1996-09-12 | 1996-10-23 | Smithkline Beecham Plc | Composition |
| US20020022657A1 (en) * | 1998-02-11 | 2002-02-21 | Francine Gervais | Methods for modulating neuronal cell death |
| NZ568553A (en) | 1998-02-11 | 2010-02-26 | Bellus Health Int Ltd | Treatment of inflammation, AB-induced cell toxicity, neuronal cell death or neuronal loss in subjects suffering from AlzheimerÆs disease |
| MXPA00011213A (es) * | 1998-05-15 | 2003-04-22 | Neurochem Inc | Uso de inhibidores de amiloides para la modulacion de la muerte de las celulas neuronales. |
| US6310073B1 (en) * | 1998-07-28 | 2001-10-30 | Queen's University At Kingston | Methods and compositions to treat glycosaminoglycan-associated molecular interactions |
| EP1276483B1 (en) * | 1999-04-28 | 2009-09-02 | BELLUS Health (International) Limited | Compositions and methods for treating amyloidosis using sulphonate derivatives |
| AU5994900A (en) | 1999-07-09 | 2001-01-30 | Isis Innovation Limited | Compounds for inhibiting diseases and preparing cells for transplantation |
| AU780624B2 (en) * | 1999-11-04 | 2005-04-07 | Andrx Corporation | Method of treating amyloid beta precursor disorders |
| BR0016652A (pt) * | 1999-12-23 | 2002-11-19 | Neurochem Inc | Métodos para inibir angiopatia amilóide cerebral, para tratar um estado de doença caracterizado por angiopatia amilóide cerebral em um indivìduo, e para diagnosticar angiopatia amilóide cerebral em um indivìduo |
| US6376557B1 (en) * | 2000-03-16 | 2002-04-23 | Chanda Bhuwalka Zaveri | Methods for treating alopecia |
| FR2832928B1 (fr) * | 2001-11-30 | 2004-02-06 | Dermo Cosmologie Lab De | Composition a base d'ester de diosgenine applicable par voie topique |
| JP4354180B2 (ja) * | 2001-12-26 | 2009-10-28 | 武田薬品工業株式会社 | 軽度認知障害治療剤 |
| US20050031651A1 (en) * | 2002-12-24 | 2005-02-10 | Francine Gervais | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| EP1585520A1 (en) * | 2002-12-24 | 2005-10-19 | Neurochem (International) Limited | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| US7253306B2 (en) * | 2003-06-23 | 2007-08-07 | Neurochem (International) Limited | Pharmaceutical drug candidates and methods for preparation thereof |
| US20060079578A1 (en) * | 2003-06-23 | 2006-04-13 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
| US7414076B2 (en) * | 2003-06-23 | 2008-08-19 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| US20050142191A1 (en) | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| US20050038000A1 (en) * | 2003-06-23 | 2005-02-17 | Xianqi Kong | Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases |
| US20050215562A1 (en) * | 2003-06-23 | 2005-09-29 | Patrick Tremblay | Methods for treating protein aggregation disorders |
| US7244764B2 (en) * | 2003-06-23 | 2007-07-17 | Neurochem (International) Limited | Methods and compositions for treating amyloid-related diseases |
| SI2089417T1 (sl) | 2006-10-12 | 2015-04-30 | Bhi Limited Partnership | Metode, spojine, sestavki in vektorji za dostavo 3-amino-1-propansulfonske kisline |
-
2004
- 2004-06-18 US US10/871,549 patent/US20050142191A1/en not_active Abandoned
- 2004-06-21 NZ NZ544685A patent/NZ544685A/en unknown
- 2004-06-21 CA CA2529268A patent/CA2529268C/en active Active
- 2004-06-21 CN CN201210156168.2A patent/CN103550196A/zh active Pending
- 2004-06-21 ES ES04744039T patent/ES2328818T3/es active Active
- 2004-06-21 PL PL04744039T patent/PL1635799T3/pl unknown
- 2004-06-21 EP EP04744039A patent/EP1635799B1/en active Active
- 2004-06-21 DE DE602004022408T patent/DE602004022408D1/de active Active
- 2004-06-21 MX MXPA05013974A patent/MXPA05013974A/es active IP Right Grant
- 2004-06-21 BR BRPI0411808-1A patent/BRPI0411808A/pt not_active Application Discontinuation
- 2004-06-21 JP JP2006516600A patent/JP4903561B2/ja active Active
- 2004-06-21 WO PCT/IB2004/002381 patent/WO2004112762A2/en active Application Filing
- 2004-06-21 AU AU2004248995A patent/AU2004248995B2/en active Active
- 2004-06-21 DK DK04744039T patent/DK1635799T3/da active
- 2004-06-21 SI SI200431261T patent/SI1635799T1/sl unknown
- 2004-06-21 PT PT04744039T patent/PT1635799E/pt unknown
- 2004-06-21 AT AT04744039T patent/ATE438391T1/de active
- 2004-06-21 EP EP09009983A patent/EP2127648A1/en not_active Withdrawn
-
2005
- 2005-11-24 IL IL172193A patent/IL172193A0/en active IP Right Grant
-
2009
- 2009-01-30 US US12/362,971 patent/US8835500B2/en active Active
-
2010
- 2010-03-31 AU AU2010201299A patent/AU2010201299A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0411808A (pt) | 2006-08-08 |
| WO2004112762A2 (en) | 2004-12-29 |
| JP4903561B2 (ja) | 2012-03-28 |
| CA2529268A1 (en) | 2004-12-29 |
| ES2328818T3 (es) | 2009-11-18 |
| EP1635799B1 (en) | 2009-08-05 |
| EP2127648A1 (en) | 2009-12-02 |
| DE602004022408D1 (de) | 2009-09-17 |
| AU2004248995B2 (en) | 2010-01-07 |
| MXPA05013974A (es) | 2006-03-09 |
| US20090182056A1 (en) | 2009-07-16 |
| CN103550196A (zh) | 2014-02-05 |
| PL1635799T3 (pl) | 2010-01-29 |
| NZ544685A (en) | 2009-05-31 |
| US20050142191A1 (en) | 2005-06-30 |
| CA2529268C (en) | 2013-10-29 |
| IL172193A0 (en) | 2009-02-11 |
| ATE438391T1 (de) | 2009-08-15 |
| JP2007518672A (ja) | 2007-07-12 |
| AU2004248995A1 (en) | 2004-12-29 |
| EP1635799A2 (en) | 2006-03-22 |
| US8835500B2 (en) | 2014-09-16 |
| SI1635799T1 (sl) | 2009-12-31 |
| WO2004112762A3 (en) | 2005-06-02 |
| PT1635799E (pt) | 2009-09-23 |
| AU2010201299A1 (en) | 2010-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL172193A0 (en) | Pharmaceutical formulations of amyloid inhibiting compounds | |
| CY2014028I1 (el) | Ενωσεις, φαρμακοτεχνικες μορφες και μεθοδοι θεραπειας ή αποτροπhς ροδοχρωμης ακμης | |
| IS8398A (is) | Lyfjasamsetningar til að meðhöndla æxli | |
| IS7691A (is) | Lyfjasamsetningar til að meðhöndla æxli | |
| BRPI0411743A (pt) | método e composições para tratar doenças relacionadas a amilóides | |
| EA200900802A1 (ru) | Способы и композиции для лечения амилоидных заболеваний | |
| DK1765388T3 (da) | Kombinationsterapi til forebyggelse eller behandling af alzheimer's sygdom, og kit dertil | |
| NO20053077D0 (no) | Terapeutiske formuleringer for behandling av beta-amyloid-relaterte sykdommer. | |
| DE602004029580D1 (de) | Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen | |
| DK2527315T3 (da) | Forbindelser, præparater og fremgangsmåder til behandling af amyloide sygdomme og synukleinopatier, såsom Alzheimers sygdom, type 2-diabetes og Parkinsons sygdom | |
| DK1660057T3 (da) | Kombinationsterapi til behandling af neovaskulære øjenlidelser | |
| DK1603633T3 (da) | Lettelse af behandling via magnetisk stimulering | |
| DK3889142T3 (da) | 1,2,4-oxadiazolbenzoesyreforbindelser og deres anvendelse til nonsense-suppression og behandling af sygdom | |
| DK1562932T3 (da) | 4 tetrazolyl-4-phenylpiperidinderivater til behandling af smerter | |
| ATE413385T1 (de) | Zur behandlung von schmerzen geeignete therapeutische mittel | |
| CY2018006I1 (el) | Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας | |
| CY1108625T1 (el) | Φαρμακευτικες συνθεσεις για τη χορηγηση απο το στομα ηπαρινης ή παραγωγων της | |
| DK1499730T3 (da) | Immunokonjugater til behandling af tumorer | |
| IS7825A (is) | Meðferðarfræðileg meðhöndlun | |
| WO2007069073A3 (en) | Pharmaceutical formulations of amyloid inhibiting compounds | |
| DK1614419T3 (da) | Midler til forebyggelse/behandling af retinale nervesygdomme, indeholdende alkyletherderivater eller salte deraf | |
| DK1687297T3 (da) | Triazindimerer til behandling af autoimmunsygdomme | |
| DE60216457D1 (de) | Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten | |
| IS8477A (is) | Beta-laktöm til að meðhöndla MTK sjúkdóma | |
| DK1485352T3 (da) | Aza-spiroforbindelser til behandling af smerter |